Brucella Vaccine: A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats.Brucella: A genus of gram-negative, aerobic bacteria that causes BRUCELLOSIS. Its cells are nonmotile coccobacilli and are animal parasites and pathogens. The bacterium is transmissible to humans through contact with infected dairy products or tissue.Brucellosis: Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.Brucella abortus: A species of the genus BRUCELLA whose natural hosts are cattle and other bovidae. Abortion and placentitis are frequently produced in the pregnant animal. Other mammals, including humans, may be infected.Brucella melitensis: A species of the genus BRUCELLA whose natural hosts are sheep and goats. Other mammals, including humans, may be infected. In general, these organisms tend to be more virulent for laboratory animals than BRUCELLA ABORTUS and may cause fatal infections.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Brucella ovis: A species of the genus BRUCELLA which are pathogenic to SHEEP.Bacterial Vaccines: Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.Vaccines, Combined: Two or more vaccines in a single dosage form.Brucella canis: A species of gram-negative bacteria infecting DOGS, the natural hosts, and causing canine BRUCELLOSIS. It can also cause a mild infection in humans.AIDS Vaccines: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.Brucellosis, Bovine: A disease of cattle caused by bacteria of the genus BRUCELLA leading to abortion in late pregnancy. BRUCELLA ABORTUS is the primary infective agent.Vaccines, Subunit: Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.Vaccines, Conjugate: Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.Malaria Vaccines: Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.Papillomavirus Vaccines: Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.Virulence: The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of an organism is determined by its VIRULENCE FACTORS.Genome, Bacterial: The genetic complement of a BACTERIA as represented in its DNA.Bacillus anthracis: A species of bacteria that causes ANTHRAX in humans and animals.Anthrax Vaccines: Vaccines or candidate vaccines used to prevent ANTHRAX.Anthrax: An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.Antigens, Bacterial: Substances elaborated by bacteria that have antigenic activity.Superoxide Dismutase: An oxidoreductase that catalyzes the reaction between superoxide anions and hydrogen to yield molecular oxygen and hydrogen peroxide. The enzyme protects the cell against dangerous levels of superoxide. EC A genus of the family POXVIRIDAE, subfamily CHORDOPOXVIRINAE, consisting of ether-sensitive viruses of leporids and squirrels. They commonly cause tumors and are usually transmitted mechanically by arthropods. MYXOMA VIRUS is the type species.Salmonella typhimurium: A serotype of Salmonella enterica that is a frequent agent of Salmonella gastroenteritis in humans. It also causes PARATYPHOID FEVER.Rift Valley Fever: An acute infection caused by the RIFT VALLEY FEVER VIRUS, an RNA arthropod-borne virus, affecting domestic animals and humans. In animals, symptoms include HEPATITIS; abortion (ABORTION, VETERINARY); and DEATH. In humans, symptoms range from those of a flu-like disease to hemorrhagic fever, ENCEPHALITIS, or BLINDNESS.Rift Valley fever virus: A mosquito-borne species of the PHLEBOVIRUS genus found in eastern, central, and southern Africa, producing massive hepatitis, abortion, and death in sheep, goats, cattle, and other animals. It also has caused disease in humans.Livestock: Domesticated farm animals raised for home use or profit but excluding POULTRY. Typically livestock includes CATTLE; SHEEP; HORSES; SWINE; GOATS; and others.Primary Care Nursing: Techniques or methods of patient care used by nurses as primary careproviders.Financing, Personal: Payment by individuals or their family for health care services which are not covered by a third-party payer, either insurance or medical assistance.Cattle: Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.Kenya: A republic in eastern Africa, south of ETHIOPIA, west of SOMALIA with TANZANIA to its south, and coastline on the Indian Ocean. Its capital is Nairobi.Academic Medical Centers: Medical complexes consisting of medical school, hospitals, clinics, libraries, administrative facilities, etc.MinnesotaIntegrative Medicine: The discipline concerned with using the combination of conventional ALLOPATHIC MEDICINE and ALTERNATIVE MEDICINE to address the biological, psychological, social, and spiritual aspects of health and illness.Health Planning Organizations: Organizations involved in all aspects of health planning activities.Awards and PrizesFinancial Support: The provision of monetary resources including money or capital and credit; obtaining or furnishing money or capital for a purchase or enterprise and the funds so obtained. (From Random House Unabridged Dictionary, 2d ed.)Organizational Affiliation: Formal relationships established between otherwise independent organizations. These include affiliation agreements, interlocking boards, common controls, hospital medical school affiliations, etc.Internet: A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.User-Computer Interface: The portion of an interactive computer program that issues messages to and receives commands from a user.Aphids: A family (Aphididae) of small insects, in the suborder Sternorrhyncha, that suck the juices of plants. Important genera include Schizaphis and Myzus. The latter is known to carry more than 100 virus diseases between plants.Computer Graphics: The process of pictorial communication, between human and computers, in which the computer input and output have the form of charts, drawings, or other appropriate pictorial representation.Software: Sequential operating programs and data which instruct the functioning of a digital computer.Programming Languages: Specific languages used to prepare computer programs.Web Browser: Software application for retrieving, presenting and traversing information resources on the World Wide Web.

Immunity to Brucella in mice vaccinated with a fraction (F8) or a killed vaccine (H38) with or without adjuvant. Level and duration of immunity in relation to dose of vaccine, recall injection and age of mice. (1/138)

Immunity to Brucella in the mouse, assessed by bacterial spleen counts 15 days after intraperitoneal inoculation of a standard challenge of B. abortus 544, has been studied with two vaccines, one experimental, composed of a fraction of the bacterial cell-wall (F8) extracted from B. abortus 99, the other of killed whole bacteria, B. melitensis 53 H38, taken as reference (H38). The level of primary immunity depended on the dose of vaccine, the presence of oil adjuvant and the age of the mouse. The presence of adjuvant enabled the immunization to F8 to continue beyond the first month, to reach its maximum around the fourth month, and to remain stable for at least 7 months. A booster injection 3 or 6 months after the primary vaccination reinforced existing immunity but did not increase it beyond a certain level. The effect of the recall injection was clearly demonstrated with low doses which gave a lower level of primary immunity.  (+info)

Antibody response to antigens distinct from smooth lipopolysaccharide complex in Brucella infection. (2/138)

The smooth lipopolysaccharide complex of the outer surface of smooth Brucella abortus cells is believed to be the antigenic component involved in serological tests routinely used for the diagnosis of brucellosis. Sera from cattle vaccinated or infected with B. abortus generally contain antibody directed toward the smooth lipopolysaccharide complex. The brucella organism contains a large number of other antigenically distinct components. The biological significance of some of these antigens has been demonstrated by showing that sera from infected cattle have precipitins to these components. These sera revealed up to seven distinct lines in immunoelectrophoresis with a protein-rich antigen mixture prepared from rough strain B. abortus 45/20, whereas sera from strain 19-vaccinated cattle did not reveal these lines at 4 or more months after vaccination. Monospecific antisera were prepared against six antigens in this mixture, and the purification of two of them by antibody affinity chromatography is described.  (+info)

Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16MDeltapurEK). (3/138)

Human brucellosis can be acquired from infected animal tissues by ingestion, inhalation, or contamination of the conjunctiva or traumatized skin by infected animal products. A vaccine to protect humans from occupational exposure or from zoonotic infection in areas where the disease is endemic would reduce an important cause of morbidity worldwide. Vaccines currently used in animals are unsuitable for human use. We tested a live, attenuated, purine-auxotrophic mutant strain of Brucella melitensis, WR201, for its ability to elicit cellular and humoral immune responses and to protect mice against intranasal challenge with B. melitensis 16M. Mice inoculated intraperitoneally with WR201 made serum antibody to lipopolysaccharide and non-O-polysaccharide antigens. Splenocytes from immunized animals released interleukin-2 (IL-2), gamma interferon, and IL-10 when cultured with Brucella antigens. Immunization led to protection from disseminated infection but had only a slight effect on clearance of the challenge inoculum from the lungs. These studies suggest that WR201 should be further investigated as a vaccine to prevent human brucellosis.  (+info)

Complement fixation test to assess humoral immunity in cattle and sheep vaccinated with Brucella abortus RB51. (4/138)

The live attenuated Brucella abortus strain RB51 is a rifampin-resistant, lipopolysaccharide (LPS) O-chain-deficient mutant of virulent B. abortus 2308. The reduced O-chain content in RB51 prevents this bacterium from inducing antibodies detectable by the conventional serologic tests for bovine brucellosis diagnosis that mainly identify antibodies to LPS. The absence of available serologic tests for RB51 also complicates the diagnosis of possible RB51 infections in humans exposed to this strain. The purpose of this study was to evaluate the suitability of a complement fixation (CF) test performed with the rough strain B. abortus RB51, previously deprived of anticomplementary activity, in detecting anti-B. abortus RB51 antibodies in cattle and sheep experimentally vaccinated with this strain. The results of this study showed that a CF test with RB51 as the antigen is able to specifically detect antibodies following RB51 vaccination in cattle and sheep. In addition, this method could be a useful tool for detecting B. abortus RB51 infection in humans.  (+info)

Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. (5/138)

Brucella abortus strain RB51 is an attenuated rough strain that is currently being used as the official live vaccine for bovine brucellosis in the United States and several other countries. We reasoned that overexpression of a protective antigen(s) of B. abortus in strain RB51 should enhance its vaccine efficacy. To test this hypothesis, we overexpressed Cu/Zn superoxide dismutase (SOD) protein of B. abortus in strain RB51. This was accomplished by transforming strain RB51 with a broad-host-range plasmid, pBBR1MCS, containing the sodC gene along with its promoter. Strain RB51 overexpressing SOD (RB51SOD) was tested in BALB/c mice for its ability to protect against challenge infection with virulent strain 2308. Mice vaccinated with RB51SOD, but not RB51, developed antibodies and cell-mediated immune responses to Cu/Zn SOD. Strain RB51SOD vaccinated mice developed significantly (P < 0.05) more resistance to challenge than those vaccinated with strain RB51 alone. The presence of the plasmid alone in strain RB51 did not alter its vaccine efficacy. Also, overexpression of SOD did not alter the attenuation characteristic of strain RB51.  (+info)

Brucella abortus strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses. (6/138)

Brucella abortus strain RB51 is a stable, rough, attenuated mutant widely used as a live vaccine for bovine brucellosis. Our ultimate goal is to develop strain RB51 as a preferential vector for the delivery of protective antigens of other intracellular pathogens to which the induction of a strong Th1 type of immune response is needed for effective protection. As a first step in that direction, we studied the expression of a foreign reporter protein, beta-galactosidase of Escherichia coli, and the 65-kDa heat shock protein (HSP65) of Mycobacterium bovis in strain RB51. We cloned the promoter sequences of Brucella sodC and groE genes in pBBR1MCS to generate plasmids pBBSODpro and pBBgroE, respectively. The genes for beta-galactosidase (lacZ) and HSP65 were cloned in these plasmids and used to transform strain RB51. An enzyme assay in the recombinant RB51 strains indicated that the level of beta-galactosidase expression is higher under the groE promoter than under the sodC promoter. In strain RB51 containing pBBgroE/lacZ, but not pBBSODpro/lacZ, increased levels of beta-galactosidase expression were observed after subjecting the bacteria to heat shock or following internalization into macrophage-like J774A.1 cells. Mice vaccinated with either of the beta-galactosidase-expressing recombinant RB51 strains developed specific antibodies of predominantly the immunoglobulin G2a (IgG2a) isotype, and in vitro stimulation of their splenocytes with beta-galactosidase induced the secretion of gamma interferon (IFN-gamma), but not interleukin-4 (IL-4). A Th1 type of immune response to HSP65, as indicated by the presence of specific serum IgG2a, but not IgG1, antibodies, and IFN-gamma, but not IL-4, secretion by the specific-antigen-stimulated splenocytes, was also detected in mice vaccinated with strain RB51 containing pBBgroE/hsp65. Studies with mice indicated that expression of beta-galactosidase or HSP65 did not alter either the attenuation characteristics of strain RB51 or its vaccine efficacy against B. abortus 2308 challenge.  (+info)

Structural, functional and immunological studies on a polymeric bacterial protein. (7/138)

The characterization of proteins from Brucella spp, the causative agent of brucellosis, has been the subject of intensive research. We have described an 18-kDa cytoplasmic protein of Brucella abortus and shown the potential usefulness of this protein as an antigen for the serologic diagnosis of brucellosis. The amino acid sequence of the protein showed a low but significant homology with that of lumazine synthases. Lumazine is an intermediate product in bacterial riboflavin biosynthesis. The recombinant form of the 18-kDa protein (expressed in E. coli) folds like the native Brucella protein and has lumazine-synthase enzymatic activity. Three-dimensional analysis by X-ray crystallography of the homolog Bacillus subtilis lumazine synthase has revealed that the enzyme forms an icosahedral capsid. Recombinant lumazine synthase from B. abortus was crystallized, diffracted X rays to 2.7-A resolution at room temperature, and the structure successfully solved by molecular replacement procedures. The macromolecular assembly of the enzyme differs from that of the enzyme from B. subtilis. The Brucella enzyme remains pentameric (90 kDa) in its crystallographic form. Nonetheless, the active sites of the two enzymes are virtually identical at the structural level, indicating that inhibitors of these enzymes could be viable pharmaceuticals across a broad species range. We describe the structural reasons for the differences in their quaternary arrangement and also discuss the potential use of this protein as a target for the development of acellular vaccines.  (+info)

Validation of the abbreviated Brucella AMOS PCR as a rapid screening method for differentiation of Brucella abortus field strain isolates and the vaccine strains, 19 and RB51. (8/138)

The Brucella AMOS PCR assay was previously developed to identify and differentiate specific Brucella species. In this study, an abbreviated Brucella AMOS PCR test was evaluated to determine its accuracy in differentiating Brucella abortus into three categories: field strains, vaccine strain 19 (S19), and vaccine strain RB51/parent strain 2308 (S2308). Two hundred thirty-one isolates were identified and tested by the conventional biochemical tests and Brucella AMOS PCR. This included 120 isolates identified as B. abortus S19, 9 identified as B. abortus strain RB51, 57 identified as B. abortus biovar 1, 15 identified as B. abortus bv. 2, 1 identified as B. abortus bv. 2 (M antigen dominant), 7 identified as B. abortus bv. 4, and 22 identified as B. abortus S2308 and isolated from experimentally infected cattle. The Brucella AMOS PCR correctly identified each isolate as RB51/S2308, S19, or a field strain of Brucella.  (+info)

  • A simple, rapid, inexpensive fluorescence polarization assay for the detection of antibodies to Brucella abortus in bulk tank milk samples at the farm level or at dairies with a sensitivity and specificity of 100 and 95.9%, respectively, is described. (
  • Animals vaccinated with pcDNA-SOD did not develop SOD-specific antibodies, at least until week 4 after immunization (the end of the experiment), and in vitro stimulation of their splenocytes with either recombinant Cu-Zn SOD or crude Brucella protein induced the secretion of gamma interferon (IFN-γ), but not interleukin-4, and elicited the induction of cytotoxic-T-lymphocyte activity. (
  • To fulfill the need for a simple and rapid diagnostic test for human brucellosis, we used the immunochromatographic lateral flow assay format to develop two assays, one for the detection of Brucella -specific immunoglobulin M (IgM) antibodies and one for the detection of Brucella -specific IgG antibodies. (
  • To address the need for a simple and rapid diagnostic test, we have applied the immunochromatographic lateral flow assay format to develop two assays, one for the detection of Brucella -specific IgM and one for Brucella -specific IgG antibodies. (
  • Since the protective antigen (PA) of B. anthracis is known to induce protective antibodies, it was decided that the objective of this research was to test whether the gene encoding PA could be expressed in Brucella producing a bivalent vaccine to protect against both brucellosis and anthrax. (
  • Evaluation of a fluorescence polarization assay for the detection of serum antibodies to Brucella abortus in water buffalo ( Bubalus bubalis ). (
  • A low-molecular-weight recombinant Brucella abortus protein reactive with antibodies from a variety of naturally and experimentally infected hosts and T lymphocytes from experimentally infected mice was identified and given the designation BA14K. (
  • Prevalence of antibodies against Brucella spp. (
  • Here, we present serological results for Baffin Bay polar bears ( Ursus maritimus ) ( n = 96) and North East Greenland muskoxen ( Ovibos moschatus ) ( n = 32) for antibodies against Brucella spp. (
  • No muskoxen had antibodies against Brucella spp. (
  • antibodies found in polar bears were due to either prey spill over or true recurrent Brucella spp. (
  • Bundle DR, Gidney MA, Perry MB, Duncan JR, Cherwonogrodzky JW (1984) Serological confirmation of Brucella abortus and Yersinia enterocolitica O:9 O-antigens by monoclonal antibodies. (
  • In particular, our strategy was to produce Brucella cell surface antigen-specific monoclonal antibodies (mAbs) for the development of an antigen capture assay for the detection of Brucella cells as potential bio threat agents in complex samples. (
  • Western blot analyses with Brucella lysate also identified antibodies against some immunodominant Brucella proteins in the serum of cattle naturally infected with Brucella spp. (
  • Brucella antibodies can persist for more than a year despite successful antibiotic treatment. (
  • To this end, monoclonal antibodies (mAbs) specific for Brucella LPS were generated and used to design a highly specific and sensitive antigen capture assay. (
  • Household blood samples were tested for Brucella antibodies using the highly sensitive Rose Bengal test (RBT) and IgM ELISA Lateral Flow Assay (LFA). (
  • Canine brucellosis is a reproductive disease caused by the bacterium Brucella cani s ( B. canis ), which can cause infertility, abortion, and severe spinal infections in dogs. (
  • The development of such a vaccine for dogs will significantly impact canine and human health by limiting the spread of B. canis . (
  • Collectively, these finding suggested that the pcDNA3.1/Hygro DNA vaccines encoding Omp25 and Omp31 genes and divalent plasmid were able to induce both humoral and cellular immunity, and had the potential to be a vaccine candidate for prevention of B. melitensis infections. (
  • Similarly to other infections caused by facultative intracellular pathogens, the induction of specific cell-mediated immunity is required for effective clearance of Brucella infections ( 4 , 22 ). (
  • The RBL supports basic research to develop drugs, diagnostics, and vaccines for emerging and reemerging infections and biodefense. (
  • Some limitations to the use of serologic tests must be taken into consideration when diagnosing Brucella infections, as most serologic assays for brucellosis show variable levels of cross-reactivity with other gram-negative bacteria (for example, E. coli O:157, Francisella tularensis , and Yersinia enterocolitica ). (
  • Brucella infections constitute a serious problem for dog breeders, pet owners, and kennels. (
  • This translates to study and innovation in medical diagnostic systems and bioassays, medical implant designs and improvement using innovative biomaterials and on-baord drug delivery, implant-related infections, surface analysis in biomedical systems, drug delivery systems for proteins and vaccines, and novel surface modification strategies. (
  • In pregnant patients, Brucella infections can be associated with miscarriage. (
  • Although Brucella is a serious pathogen, type I, II, and III secretion systems and pathogenicity islands were absent. (
  • In Marseille, France, his research is centered on combating Infectious diseases by studying host/pathogen interactions and vaccine design. (
  • To describe the safety of the 2016-2017 formulation of Fluzone Quadrivalent vaccine in children 3 to (
  • The aim of the study is to evaluate the safety and immunogenicity of the 2015-2016 formulations of Fluzone Quadrivalent and Fluzone Intradermal Quadrivalent vaccines in adults 18 to (
  • The study will evaluate the safety and immunogenicity of the 2015-2016 formulation of Fluzone Quadrivalent vaccine, administered in a 1- or 2-dose schedule, in accordance with the Advisory. (
  • Quadrivalent Meningococcal Vaccine Uptake Among Men Who Have Sex With Men During a Meningococcal Outbreak in Los Angeles County, California, 2016-2017. (
  • Deletion of these genes reduces Brucella virulence, but they maintain excellent immunogenicity to activate the host immune response. (
  • Although the available vaccines are effective in controlling brucellosis, they have numerous drawbacks like abortifacient potential for pregnant animals (Smith and Ficht, 1990), residual virulence ability for human (Spink et al. (
  • 1970). The major drawback of chemically killed vaccines include high production cost, poor protection, residual virulence, batch to batch variation, denaturation of conformational epitopes, unaccepted local reaction, serological problems (Moriyon et al. (
  • Six groups of BALB/c mice (seven mice per group) were intramuscularly injected with three recombinant constructs, native pcDNA3.1/Hygro (+) and phosphate-buffered saline (PBS) as controls and subcutaneous injection of attenuated live vaccine Rev1. (
  • Several new generation vaccines like recombinant vaccine (Al-Mariri et al. (
  • Studies employing both purified subunit preparations and live, recombinant antigen delivery systems should allow a comprehensive evaluation of the relative importance of specific Brucella proteins in eliciting protective immunity. (
  • In an attempt to identify Brucella proteins capable of inducing protective immune responses, a collection of recombinant Escherichia coli clones expressing Brucella proteins reactive in immunoassays with sera from a variety of experimentally and naturally infected hosts was assembled ( 18 ). (
  • One of these clones, which was designated IV-4, produced a recombinant Brucella protein with an apparent molecular mass of 14 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. (
  • 1999. Oral vaccination of white-tailed deer using a recombinant bacillus Calmette-Guerin vaccine expressing the Borrelia burgdorferi outer surface protein A: prospects for immunocontraception. (
  • In particular, a total of 25 target genes are involved in regulating apoptosis and autophagy, indicating that these miRNAs may play important regulatory roles in the Brucella -host interactions. (
  • Authors: Zaitoon H, Bamberger E, Yaniv L, Mendelson B, Srugo I, Chistyakov I Abstract BACKGROUND: The introduction of pneumococcal conjugate vaccine-13 (PCV-13) has reduced the burden of invasive pneumococcal disease. (
  • Antibody response and antigen-specific gamma-interferon profiles of vaccinated and unvaccinated pregnant sheep experimentally infected with Brucella melitensis . (
  • Antibody to the O-polysaccharide of Brucella LPS has been firmly established as an important mediator of anti- Brucella effects in murine models of secondary immunity [ 13 , 14 ]. (
  • Our aim was to specifically detect Brucellae with 'smooth' lipopolysaccharide (LPS) using a highly sensitive monoclonal antibody (mAb) based immunological assay. (
  • This study will evaluate whether it is possible to generate baseline biomarker-based prediction rules (PdR) for vaccine response (post baseline absolute serum antibody titer) using each of. (
  • Here, with the support of a recently awarded $458,000 National Institutes of Health grant, Caswell studies the elusive activities of a bacterium called Brucella. (
  • With this latest grant, we will examine the unique genetic circuitry of Brucella, and how it allows the bacterium to trick, invade, and live inside immune cells," said Caswell, an assistant professor of bacteriology in the Virginia-Maryland College of Veterinary Medicine and a Fralin Life Science Institute affiliate. (
  • In this study, the outer membrane proteins (Omps) of Brucella melitensis 152, 183 and 293 of local isolates were extracted and characterized using Sodium Dodecyl Sulfate-polyacrylamide Gel Electrophoresis (SDS-PAGE). (
  • We also tried to generate mAbs against Brucella cell surface proteins from mice immunised with inactivated whole Brucella cells. (
  • however, identification of the recognised proteins with a Brucella-specific peptide microarray failed. (
  • Currently, these investigators ( 44 ) are evaluating the proteomic expression of Brucella to identify the bacterial proteins expressed in vitro. (
  • The SciMiner tool, originally designed for detecting mammalian gene/protein names in text, was extended to identify host and Brucella gene/protein names in the abstracts. (
  • Brucella outer membrane protein 2b (Omp2b) is a 36 kD porin existed in common Brucella pathogens and it is considered as priority antigen for designing a new subunit vaccine. (
  • In the current study, we aimed to predict and analyze the secondary and tertiary structures of the Brucella abortus Omp2b protein, and to predict T-cell and B-cell epitopes with the help of bioinformatics tools. (
  • Our results indicate that Omp2b protein has a potential to induce both B-cell- and T-cell-mediated immune responses and it can be evaluated as a new subunit vaccine candidate against brucellosis. (
  • A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. (
  • For decades, a live vaccine has been successfully used in risk groups but is presently not available due to difficulties in standardisation. (
  • Future studies to define the role of these secretion systems in Brucella intracellular survival will be necessary before we can understand the mechanisms of Brucella pathogenesis. (
  • As a specialist of bacterial pathogenesis, he is the one who characterized the replication niche of Brucella and also identified host partners of Salmonella effectors secreted by the type III secretion system. (
  • Genetic trans-complementation using a plasmid-based expression of Brucella manBA successfully restored O-polysaccharide expression in only one-third of O-polysaccharide deficient spontaneous mutants. (
  • Delineation of the immune mechanisms responsible for vaccine-induced protection may focus subunit vaccine development by suggesting potential immune correlates and adjuvants tailored to evoke a desired response. (
  • Based on these results, we conclude that i.s. immunization with pcDNA-SOD vaccine efficiently induced a Th1 type of immune response and a protective response that could be related to IFN-γ production and cytotoxic activity against infected cells by SOD-specific CD4 + and CD8 + T cells, respectively. (
  • The exact mechanism for protective ability of this candidate vaccine has been poorly understood. (
  • Therefore, the identification of Brucella cellular components which contribute to the induction of protective responses in the host will be an important step in designing improved vaccines. (
  • Total B. abortus S544 counts in the spleen of each animal collected on the 7th day of challenge was determined to evaluate the protective index (PI) of anti- Brucella serum by statistical analysis. (
  • In order to place the isolate more accurately, a multilocus sequencing approach was applied, which confirmed that the isolate represented a novel member of the emerging 'atypical' Brucella group, which includes isolates from human disease, from rodents and, more recently, reported isolations from frogs in Germany. (
  • This section provides a summary of identification, serological and other tests, vaccines and diagnostic biologicals drawn from Chapter 2.3.1 of the OIE Manual of Standards for Diagnostic Tests and Vaccines (OIE, 2000). (